RAB34 and colorectal carcinoma: These results combined with the survival analysis indicated that RAB34 is an unfavorable prognostic factor, more importantly, targeting RAB34 might provide a novel therapeutic strategy to improve the responses to anti-PD-1 therapy in CRC.